Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Spiracur was a medical device company that specialized in the development of innovative wound healing technologies, specifically focusing on negative pressure wound therapy (NPWT). The company's flagship product, the SNaP (Smart Negative Pressure) Wound Care System, was a non-powered, portable device designed to treat chronic and acute wounds. Unlike traditional NPWT systems that require heavy electronic pumps and batteries, the SNaP system utilized a proprietary mechanical spring mechanism to create suction, offering a lightweight and silent alternative for patients. This technology significantly improved patient mobility and quality of life while maintaining clinical efficacy in wound closure. Spiracur was acquired by Acelity (KCI) in 2015 to bolster their portfolio of portable and disposable wound care solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Spiracur.